Grown from a single-product start-up into a
6-brand consumer healthcare company. Revenue on track to double in 2026.
Stocked by the UK’s leading pharmacy & grocery chains, including Boots, Superdrug, Asda, Morrisons, Tesco, and Day Lewis.
Rapid year-on-year growth and a primed pipeline of new products to drive incremental revenue.
62% CAGR 2022-2025.
Who we are
Maxwellia is leading the next wave in consumer healthcare, creating social impact and commercial scale at the same time.
We convert prescription drugs into consumer friendly over-the-counter (OTC) brands, and we do it quickly and efficiently using our proven DynamicSwitch™ process; empowering consumers to take control of their health while driving transformative growth in the $193bn global OTC market.
Backed by prominent investors, including PXN, Channel 4 Ventures and the British Business Bank, along with the highly successful private investor, John Gunn, Maxwellia is uniquely positioned to lead the next wave of consumer healthcare innovation.
Market Opportunity
2026 funding round open
With a growing portfolio, strong retailer partnerships, and a proven repeatable model, Maxwellia is seeking investment to accelerate into its next phase of growth.
Capital raised from this funding round will be directed towards expanding distribution, driving new product development and line extensions, strengthening brand activation, and further building the team to unlock additional revenue opportunities.
Register now to receive the Investor Memorandum
ABOUT YOUR EIS INVESTMENT
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment.
Your investment in Maxwellia can benefit from the Enterprise Investment Scheme (EIS). EIS offers a range of benefits to investors:
Maxwellia is a Knowledge-Intensive Company
1. Income Tax Relief
Investors can claim up to 30% relief on investments in EIS-qualifying shares, up to £1 million annually (£2 million for Knowledge-Intensive Companies). The investment must be held for at least 3 years, and investors can "carry back" the relief to the previous tax year.
2. Capital Gains Tax (CGT) Freedom
No CGT is payable on shares sold after 3 years if income tax relief was received
and not withdrawn.
3. CGT Deferral Relief
Investors can defer CGT on gains from other assets by investing in EIS shares. The deferral lasts as long as the EIS shares are held.
4. Loss Relief
If shares are sold at a loss, the loss can be offset against capital gains or income, reducing the investment risk.
5. Business Relief for Inheritance Tax (IHT)
EIS shares may qualify for 100% IHT relief after 2 years, potentially eliminating inheritance tax on the investment.